title: ECVAM prevalidation study on in vitro cell transformation assays: general outline and conclusions of the study.
abstract: The potential for a compound to induce carcinogenicity is a key consideration when ascertaining hazard and risk assessment of chemicals. Among the in vitro alternatives that have been developed for predicting carcinogenicity, in vitro cell transformation assays (CTAs) have been shown to involve a multistage process that closely models important stages of in vivo carcinogenesis and have the potential to detect both genotoxic and non-genotoxic carcinogens. These assays have been in use for decades and a substantial amount of data demonstrating their performance is available in the literature. However, for the standardised use of these assays for regulatory purposes, a formal evaluation of the assays, in particular focusing on development of standardised transferable protocols and further information on assay reproducibility, was considered important to serve as a basis for the drafting of generally accepted OECD test guidelines. To address this issue, a prevalidation study of the CTAs using the BALB/c 3T3 cell line, SHE cells at pH 6.7, and SHE cells at pH 7.0 was coordinated by the European Centre for the Validation of Alternative Methods (ECVAM) and focused on issues of standardisation of protocols, test method transferability and within- and between-laboratory reproducibility. The study resulted in the availability of standardised protocols that had undergone prevalidation [1,2]. The results of the ECVAM study demonstrated that for the BALB/c 3T3 method, some modifications to the protocol were needed to obtain reproducible results between laboratories, while the SHE pH 6.7 and the SHE pH 7.0 protocols are transferable between laboratories, and results are reproducible within- and between-laboratories. It is recommended that the BALB/c 3T3 and SHE protocols as instituted in this prevalidation study should be used in future applications of these respective transformation assays. To support their harmonised use and regulatory application, the development of an OECD test guideline for the SHE CTAs, based on the protocol published in this issue, is recommended. The development of an OECD test guideline for the BALB/c 3T3 CTA should likewise be further pursued upon the availability of additional supportive data and improvement of the statistical analysis.
authors.affiliation: Institute for Health and Consumer Protection, European Commission Joint Research Centre, Ispra, Italy. rafaella.corvi@jrc.ec.europa.eu
authors.forename: Raffaella
authors.initials: R
authors.lastname: Corvi
authors.forename: Marilyn J
authors.initials: MJ
authors.lastname: Aardema
authors.forename: Laura
authors.initials: L
authors.lastname: Gribaldo
authors.forename: Makoto
authors.initials: M
authors.lastname: Hayashi
authors.forename: Sebastian
authors.initials: S
authors.lastname: Hoffmann
authors.forename: Leonard
authors.initials: L
authors.lastname: Schechtman
authors.forename: Philippe
authors.initials: P
authors.lastname: Vanparys
mesh_terms: D000826:Animal Testing Alternatives / Q000379:methods* / Q000592:standards; D000818:Animals; D041702:BALB 3T3 Cells; D015197:Carcinogenicity Tests / Q000379:methods* / Q000592:standards; D002273:Carcinogens / Q000633:toxicity; D002471:Cell Transformation, Neoplastic; D006224:Cricetinae; D008647:Mesocricetus; D051379:Mice; D015203:Reproducibility of Results; D054928:Validation Studies as Topic
chemical_list: D002273:Carcinogens